medigraphic.com

2025, Número 1

<< Anterior Siguiente >>

Rev Hematol Mex 2025; 26 (1)


Principales bacterias aisladas en cultivos de pacientes con leucemia aguda y neutropenia febril en un hospital terciario de Puebla, México

Hernández OEJ, Silva RR, Montiel JÁJ, Solís PJC, Sánchez TNB, Martínez OMD, Alcocer OSA

Idioma: Español
Referencias bibliográficas: 23
Paginas: 1-8
Archivo PDF: 400.19 Kb.


RESUMEN

OBJETIVO: Conocer la prevalencia de bacterias grampositivas y gramnegativas en cultivos (hemocultivo y urocultivo) de pacientes con leucemia aguda y neutropenia febril en un hospital terciario de Puebla, México.
MATERIALES Y MÉTODOS: Estudio observacional y prospectivo, efectuado en pacientes mayores de 18 años con leucemia aguda y neutropenia febril, a quienes se les realizaron hemocultivos y urocultivos en el Hospital de Especialidades Puebla, General de División Manuel Ávila Camacho, México, de febrero a julio de 2023.
RESULTADOS: De 180 pacientes con leucemia aguda y neutropenia, solo 87 manifestaron fiebre. Los hemocultivos fueron positivos en 27 (31%) pacientes, Escherichia coli se aisló en 16 (18.3%). Los urocultivos fueron positivos en 21 (24.1%) pacientes, E. coli se identificó en 11 (12.6%). Solo 2 (2.2%) urocultivos no fueron reportados.
CONCLUSIONES: En la mayoría de los pacientes con leucemia aguda y neutropenia febril no se identificó un patógeno bacteriano. No hubo desarrollo bacteriano en 60 (68.9%) hemocultivos y 64 (73.5%) urocultivos. E. coli fue el patógeno bacteriano aislado con mayor frecuencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Keng MK, Sekeres MA. Febrile neutropenia in hematologicmalignancies. Curr Hematol Malig Rep 2013; 8 (4): 370-8.https://doi.org.10.1007/s11899-013-0171-4

  2. Klastersky J, Naurois J De, Rolston K, et al. Clinical practiceguidelines management of febrile neutropaenia:ESMO Clinical practice guidelines. Ann Oncolog 2016;27 (Supplement 5): v111-8. https://doi.org.10.1093/annonc/mdw325

  3. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient managementof fever and neutropenia in adults treated formalignancy: American Society of Clinical Oncology andInfectious Diseases Society of America Clinical PracticeGuideline Update. J Clin Oncol 2018; 36 (14): 1443-53.https://doi.org.10.1200/JCO.2017.77.6211

  4. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxisand outpatient management of fever and neutropeniain adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clinl Oncol 2013; 31(6): 794-810. https://doi.org.10.1200/JCO.2012.45.8661

  5. Jacob LA, Lakshmaiah KC, Govindbabu K, et al. Clinicaland microbiological profile of febrile neutropenia insolid tumors and hematological malignancies at a tertiarycancer care center in South India. Indian J Cancer2014; 51 (4): 464-468. https://doi.org.10.4103/0019-509X.175330

  6. Zimmer AJ, Freifeld AG. Optimal management of neutropenicfever in patients with cancer. J Oncol Pract 2019; 15(1): 19-24. https://doi.org.10.1200/JOP.18.00269

  7. Francesc Escrihuela V, Laporte J, Albasanz-puig A. Updateon the management of febrile neutropenia in hematologicpatients. Rev Esp Quimioter 2019; 32 (Suppl. 02): 55-8.

  8. Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, etal. SEOM clinical practice guideline: management and preventionof febrile neutropenia in adults with solid tumors(2018). Clin Transl Oncol 2019; 21 (1): 75-86. https://doi.org.10.1007/s12094-018-1983-4

  9. Thowinson M, Hernández A. Neutropenia febril inducidapor quimioterapia e infecciones asociadas: una revisión dela literatura. Gac Mex Oncol 2019; 18 (4): 328-333.

  10. Zahid KF, Hafeez H, Afzal A. Bacterial spectrum and susceptibilitypatterns of pathogens in adult febrile neutropenicpatients: a comparison between two time periods. J AyubMed Coll Abbottabad 2009; 21 (4): 146-9.

  11. Rajendranath R, Balasubramaniyum VKK, Vijayakumar V,et al. Factors predicting outcome in high risk febrile neutropeniain patients receiving intensive chemotherapy foracute sleukemia: A prospective, observational study fromSouth India. Indian J Cancer 2014; 51 (4): 481-486. https://doi.org.10.4103/0019-509X.175303

  12. Al-Ahwal MS, Al-Sayws F, Johar I. Febrile neutropeniacomparison between solid tumours and hematologicalmalignancies. PAN Arab Med 2005; 2: 4-7.

  13. National Comprehensive Cancer Network. NCCN ClinicalPractice Guidelines in Oncology: Prevention and Treatmentof Cancer-Related Infections. Plymouth Meeting (PA):NCCN; Versión 3.2024.

  14. Kaushansky K. Williams hematology. Tenth edit. New York:McGraw Hill; 2021.

  15. Calik S, Ari A, Bilgir O, et al. The relationship betweenmortality and microbiological parameters in febrile neutropenicpatients with hematological malignancies. SaudiMed J 2018; 39 (9): 878-885. https://doi.org.10.15537/smj.2018.9.22824

  16. Green JR, Carpenter SL. Consultative hematology 1:hospital-based and selected outpatient topics. AmericanSociety of Hematology. Self-Assessment Program. 8thWashington, 2022: 34-62.

  17. Gudiol C, Aguilar-Guisado M, Ramón J, et al. Executivesummary of the consensus document of the SpanishSociety of Infectious Diseases and Clinical Microbiology(SEIMC), the Spanish Network for Research in InfectiousDiseases (REIPI) and the Spanish Society of Haematologyand Haemotherapy (SEHH) on the management of febrileneutropenia in patients with hematological malignancies.Enfermedades Infecciosas Microbiología Clínica 2020; 38(4): 174-181. https://doi.org.10.1016/j.eimc.2019.01.013

  18. Guarana M, Nucci M, Nouér SA. Shock and early death inhematologic patients with febrile neutropenia. AntimicrobAgents Chemother 2019; 63 (11). https://doi.org.10.1128/AAC.01250-19

  19. Mikulska M, Averbuch D, Tissot F, et al; European Conferenceon Infections in Leukemia (ECIL). Fluoroquinolone prophylaxisin haematological cancer patients with neutropenia:ECIL critical appraisal of previous guidelines. J Infect 2018;76 (1): 20-37. https://doi.org.110.1016/j.jinf.2017.10.009

  20. Bosnak C, Akova M. Febrile neutropenia managementin high-risk neutropenic patients: a narrative review onantibiotic prophylaxis and empirical treatment. Expert RevAnti-infective Ther 2025; 1-15. https://doi.org.10.1080/14787210.2025.2487149

  21. Aguilar-Guisado M, Espigado I, Martín-Peña A, et al. Optimisationof empirical antimicrobial therapy in patients withhaematological malignancies and febrile neutropenia (howlong study): an open-label, randomised, controlled phase4 trial. Lancet Haematol 2017; 4 (12): e573-e583. https://doi.org.10.1016/S2352-3026(17)30211-9

  22. Gustinetti G, Mikulska M. Bloodstream infection in neutropeniccancer patients: A practical update. Virulence2016; 7 (3): 280-297. https://doi.org.10.1080/21505594.2016.1156821

  23. Ferreira JN, Correia LRBR, Oliveira RM, et al. Managingfebrile neutropenia in adult cancer patients: an integrativereview of the literature. Rev Bras Enferm 2017; 70 (6):1301-1308. https://doi.org.10.1590/0034-7167-2016-0247




2020     |     www.medigraphic.com